Related Experiment Video
Updated: Jan 20, 2026
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
Elizabeth K Lee1, Panagiotis A Konstantinopoulos2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Abstract:
Recent studies have demonstrated that, besides direct cytotoxic effects, poly(ADP ribose) polymerase (PARP) inhibitors (PARPis) exhibit antitumor immunity that occurs in a stimulator of interferon genes (STING)-dependent manner and is augmented by immune checkpoint blockade (CPB). In ovarian cancer, combined PARP and immune checkpoint inhibition has yielded encouraging preliminary results in two early-phase clinical trials and is currently being evaluated in both first-line and recurrent settings.
Insights
Poly(ADP ribose) polymerase inhibitors (PARPis) boost antitumor immunity via stimulator of interferon genes (STING) pathways. Combining PARPis with immune checkpoint blockade shows promise in ovarian cancer clinical trials.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Poly(ADP ribose) polymerase inhibitors (PARPis) are established cancer therapeutics.
- Emerging evidence suggests PARPis modulate the tumor immune microenvironment.
- Stimulator of interferon genes (STING) pathway activation is crucial for innate immune responses.
Purpose of the Study:
- To investigate the immunomodulatory effects of PARPis beyond direct cytotoxicity.
- To explore the role of the STING pathway in PARPi-mediated antitumor immunity.
- To evaluate the efficacy of combining PARPis with immune checkpoint blockade (CPB) in ovarian cancer.
Main Methods:
- Utilized preclinical models and clinical trial data.
- Assessed STING-dependent immune activation.
- Analyzed responses to combined PARPi and CPB therapies.
Main Results:
- PARPis induce STING-dependent antitumor immunity.
- Combined PARPi and CPB synergistically enhance anti-tumor responses.
- Early-phase clinical trials in ovarian cancer show encouraging results.
Conclusions:
- PARPis possess significant immunomodulatory properties.
- Combination therapy with CPB represents a promising strategy for ovarian cancer.
- Further clinical evaluation in first-line and recurrent settings is warranted.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Related Concept Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
08:26Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
11:51Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
05:42An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum